Overview

Zanamivir Versus Trivalent Split Virus Influenza Vaccine

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
This unblinded pilot study is intended to assess the feasibility of a larger double-blind, randomized control trial. For the larger trial the investigators are interested in understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors for influenza infection in healthy adults, and in assessing the safety and tolerability of seasonal antiviral prophylaxis in healthcare workers. The pilot study will be assessing the rate of infection with influenza and the rate of adherence to long-term zanamivir in 60 healthy volunteers.
Phase:
Phase 3
Details
Lead Sponsor:
Mount Sinai Hospital, Canada
Collaborator:
GlaxoSmithKline
Treatments:
Antiviral Agents
Vaccines
Zanamivir